WELLINGTON, New Zealand, March 3, 2025 /PRNewswire/ — Volpara Well being, a world chief in AI-powered breast well being options and a subsidiary of Lunit, right this moment introduced three main milestones:
-
Craig Hadfield, Volpara’s Chief Buyer and Monetary Officer, will turn into CEO on April 1, succeeding Teri Thomas as she pursues her subsequent profession steps.
-
Volpara density is now a validated enter to the BOADICEA breast most cancers danger mannequin.
-
A report of 21 unbiased abstracts that includes Lunit and Volpara options had been introduced at ECR 2025.
CEO transition
Teri Thomas, who has led Volpara since 2022, performed a key function within the firm’s transformation, strengthening its AI platform and overseeing its 2024 acquisition by Lunit. Beneath her management, the corporate grew annual recurring income to over $34 million.
“We deeply respect Teri’s management and affect,” stated Hadfield. “She has positioned Volpara for continued success, and we want her nicely in her subsequent part.”
Reflecting on her tenure, Teri acknowledged, “It has been an honor to guide Volpara and work with an unbelievable crew advancing AI-driven breast well being options. Whereas I am excited for my subsequent chapter, I stay a robust supporter of Volpara’s mission.”
Hadfield has been instrumental in Volpara’s monetary progress, SaaS transition, and strategic acquisitions. “I am honored to guide Volpara into its subsequent part of innovation and affect,” stated Craig. “I look ahead to working with our crew, companions, and clients to advance breast well being.”
Volpara density now built-in into BOADICEA breast most cancers danger mannequin
Volpara volumetric breast density evaluation is now a validated enter to the newly launched model of the BOADICEA breast most cancers danger mannequin. This marks a major milestone, as Volpara density is now built-in into two totally different breast most cancers danger fashions named within the NCCN pointers—Tyrer-Cuzick, and BOADICEA, typically known as CanRisk, its internet software.
Any Volpara clients can use their Volpara density info through CanRisk right this moment. CanRisk is endorsed by worldwide societies and pointers to be used in Australia, the EU, the UK, and Canada. Research have proven using Volpara density in BOADICEA to enhance mannequin accuracy in comparison with utilizing BI-RADS density classes, enhancing breast most cancers danger evaluation capabilities for healthcare suppliers worldwide.
A record-high 21 Lunit and Volpara analysis abstracts at ECR 2025
At ECR 2025, Lunit and Volpara’s options had been featured in a record-high 21 unbiased analysis abstracts. This milestone highlights the rising affect of AI-driven breast well being options within the international radiology neighborhood, reinforcing Volpara’s and Lunit’s dedication to advancing most cancers detection and affected person care via innovation and scientific analysis.
